Gufic Biosciences (BOM:509079) Total Liabilities: ₹6,774 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:509079 Gufic Biosciences Ltd BOM:509079
77 GF Score
Price ₹387.95
GF Value ₹409.35
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Gufic Biosciences Total Liabilities?

Gufic Biosciences BOM:509079 -2.07% 77 Total Liabilities is ₹6,774 Mil as of Mar. 2026. GuruFocus rates BOM:509079 with a GF Score™ of 77/100 and a GF Value™ of ₹409.35 (Fairly Valued). The stock has 7 warning signs investors should review.

Gufic Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 was ₹6,774 Mil.

Gufic Biosciences's quarterly Total Liabilities declined from Sep. 2025 (₹6,399.43 Mil) to Dec. 2025 (₹0.00 Mil) but then increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹6,773.87 Mil).

Gufic Biosciences's annual Total Liabilities increased from Mar. 2024 (₹5,599.81 Mil) to Mar. 2025 (₹5,682.87 Mil) and increased from Mar. 2025 (₹5,682.87 Mil) to Mar. 2026 (₹6,773.87 Mil).

Gufic Biosciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Gufic Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gufic Biosciences Total Liabilities Chart

Gufic Biosciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,522.84 5,133.51 5,599.81 5,682.87 6,773.87

Gufic Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,682.87 0.00 6,399.43 0.00 6,773.87
BOM:509079
77GF Score
Gufic Biosciences Ltd BOM:509079
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gufic Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Gufic Biosciences's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5178.49+(1194.085+401.298
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=6,774

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=13423.74-6649.867
=6,774

Gufic Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5178.49+(1194.085+401.298
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=6,774

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=13423.74-6649.867
=6,774

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₹6,774 Mil mean?
Gufic Biosciences (BOM:509079) has a Total Liabilities of ₹6,774 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Gufic Biosciences and its competitors.
Is Gufic Biosciences' Total Liabilities too high?
Gufic Biosciences' current Total Liabilities is ₹6,774 Mil. Overall, Gufic Biosciences has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gufic Biosciences' Total Liabilities compare to ZTS and UTHR?
Gufic Biosciences' Total Liabilities of ₹6,774 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Gufic Biosciences and its competitors. Gufic Biosciences's current Total Liabilities is ₹6,774 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gufic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Gufic Biosciences (BOM:509079) is currently considered Fairly Valued. The stock's GF Value™ is ₹409.35, compared to a current price of ₹387.95 — trading 5.2% below its estimated fair value. The current Total Liabilities is ₹6,774 Mil. Gufic Biosciences' overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Gufic Biosciences (BOM:509079), the current Total Liabilities is ₹6,774 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gufic Biosciences (BOM:509079) Overvalued in 2026?

Based on GuruFocus' analysis, Gufic Biosciences stock appears to be undervalued. The current stock price of ₹387.95 is trading 5.2% below its estimated GF Value™ of ₹409.35. GuruFocus considers Gufic Biosciences to be Fairly Valued.

Key valuation signals for BOM:509079:

  • Total Liabilities: ₹6,774 Mil
  • GF Value™: ₹409.35 vs. price of ₹387.95 (5.2% below fair value)
  • GF Score™: 77/100 with 7 warning signs

No single metric tells the full story. See the BOM:509079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gufic Biosciences Business Description

Other Exchanges GUFICBIO:India
Address SM House, 11 Sahakar Road, 1st to 4th Floor, Vile Parle (East), Mumbai, MH, IND, 400 057
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
77GF Score

Get the complete analysis for BOM:509079

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹387.95
Price
₹409.35
GF Value